Abstract: The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed.

Abstract: The present invention relates to a composition for prevention or treatment of hair loss. The composition is effectively delivered into hair papilla cells in a hair loss area, which is a target area, wherein a cytokine or enzyme highly expressed in the hair loss area causes a drug to be separated from a compound contained in the composition so that the drug effectively exhibits activity, which ultimately promotes hair growth and/or hair regrowth.

Abstract: The present invention relates to a fusion protein comprising an extracellular domain of leucine-rich and immunoglobulin-like domains-1 (Lrig-1) protein and an immunoglobulin Fc region. The fusion protein provided in the present invention can interact with a ligand for Lrig-1 protein, which is present on effector T cells, to inhibit the interaction between the effector T cells and regulatory T cells (Treg cells) having the Lrig-1 protein on their surface, so that activity of the regulatory T cells is inhibited and activity of the effector T cells is maintained or elevated, thereby effectively inhibiting growth of cancer cells, in particular, solid cancer cells.

Abstract: The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed.

Abstract: The present invention relates to a composition and a fusion protein for prevention or treatment of autoimmune diseases, which contain a Smad protein, and provides a method for prevention or treatment of autoimmune diseases, including lupus nephritis and rheumatoid arthritis.

Abstract: The present invention relates to a novel fusion protein comprising the transcription modulation domain of the transcription factor NF-?B subunit p65 and a protein transduction domain and to the use thereof. The fusion protein of the present invention has the effects of inhibiting the transcription of NF-?B and IL-2 by competitive inhibition and inhibiting the LPS-induced secretion of inflammatory cytokines and also inhibiting the production of IL-2, IFN-?, IL-4, IL-17A and IL-10 in splenocytes, and thus is effectively used as a composition for the prevention or treatment of a disease related to NF-?B overactivity.